Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotrokinra in active psoriatic arthritis
ISRCTN16757143Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2025
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in psoriatic arthritis (PsA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: ACR20 response at Week 16. Started Mar 2025; status: active, not recruiting.
02
Drugs
icotrokinra
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on ISRCTN16757143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16757143.